Logotipo de Valence
populares
Iniciar sesión
Loading data for IMMX — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

Immix Biopharma Inc.

NasdaqCM: IMMX · Precio en tiempo real · USD
13.16
-0.03 (-0.23%)
Al cierre: Aug 20, 2026, 8:00 PM
13.00
-1.22%
Premercado: 5:48 AM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

Immix Biopharma Inc. (IMMX): cotización, análisis y datos

-0.23%

No hay datos disponibles

Precio de compra9.37
Capitalización de mercado936.86M
Ingresos (TTM)n/a
Beneficio neto (TTM)-39.92M
0.11
-0.88
n/a
-14.56
P/B (TTM)4.11
P/S (TTM)n/a
Fecha de resultadosn/a
Precio de venta16.42
Volumen1,665,599
Volumen medio (20D)1,843,566
Abierto12.98
Anterior Cerrar13.19
Rango del día12.69 - 13.20
Rango de 52 semanas1.94 - 13.20
analistan/a
Precio objetivon/a
Dividendosn/a
Fecha ex dividendon/a

Acerca de IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California....

[Leer más]
Industria Biotechnology
Sector Healthcare
IPO Fecha Dec 16, 2021
Empleados 21
Bolsa de Valores NasdaqCM
Símbolo bursátil IMMX
Sitio web https://www.immixbio.com
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Immix Biopharma fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -29.44M, un aumento de 36.21%.

Estados financieros

Sorpresa de resultados

Immix Biopharma ha publicado sus resultados trimestrales en Aug 7, 2026:
  • Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
  • EPS de -0.18 falla las estimaciones por 0.00, con 18.18% Crecimiento interanual.
    news image

    1 mes hace · Investor's Business Daily

    Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

    One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

    news image

    2 meses hace · Zacks

    Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

    The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...

    news image

    2 meses hace · Simply Wall St.

    Exploring 3 High Growth Tech Stocks in the US Market

    Over the last 7 days, the United States market has dropped 2.7%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying...

    news image

    2 meses hace · Zacks

    Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

    The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

    news image

    3 meses hace · Simply Wall St.

    3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%

    Over the last 7 days, the United States market has risen by 1.5%, contributing to a remarkable 26% climb over the past year, with earnings forecasted to grow by 17% annually. In this flourishing envir...

    Página 1 de 2